Milestones

• 2018
  • Peginterferon alfacon-2 Injection approved by NMPA
  • NDA Submission of coblopasvir
  • Ukrainian GMP recertification of manufacture facility at No.7 Rongchang Street east
  • GMP recertification of multiple products and formulations
  • National High-tech Enterprise recertification
• 2017
  • Submission of the first China’s generic sofosbuvir tablet for ANDA
  • Submission of generic pirfenidone tablet for ANDA
  • Strategic partnership with Gaolin Capital
  • Designation of Beijing BDA Innovation Workshop
  • GMP recertification of multiple formulations at No. 7 Rongchang Street East site
• 2016
  • Dr. Zhou Desheng enrolled in the second batch of the national "Million Talents Plan".
  • China's first generic sofosbuvir raw materials and tablets were granted clinical trial approval.
  • The investigative new drug KW-136 with independent intellectual property rights granted CTA.
  • Established “Beijing Municipal Engineering Laboratory of Liver Disease Therapeutic Drug Research”.
  • Enrolled in the first batch of the 13th Five-Year Plan "Beijing Biopharmaceutical Industry Breakthrough Development Project (G20 Project)".
• 2015
  • Dr. Zhou Desheng was nominated as Innovative Entrepreneurial Talent of Ministry of Science and Technology of the People’s Republic of China.
  • Certified by Colombian INVIMA GMP.
  • Introduced Eli Lilly Strategic Investment.
  • Invested GinkgoPharma（Suzhou）Co., Ltd.
• 2014
  • Certified as "Beijing Patent Demonstration Unit".
  • Be the first sponsor of generic Sofosbuvir trial in China.
  • Applied an IND for KW-136 with independent intellectual property rights.
  • Selected as "Beijing Biomedical Industry Crossing Development Project (G20 Project)".
  • Enrolled in "Beijing Biopharmaceutical Industry Breakthrough Development Project(G20 Project)".
  • Established "Beijing municipal International Scientific & Technological collabration Base –Preventative & Therapeutic New Drug of Liver Disease."
• 2013
  • Dr. Hai Pan, VP of R&D, was nominated as China’s national “Recruitment Plan of Global Experts”, a prestigious program for overseas talents.
  • Launched a new product– recombinant human interferon alfa-2b effervescent tablet, China’s first-ever commercialized interferon product in this dosage form.
• 2012
  • Formed a strategic partnership with Haitong Capital and Cybernaut.
  • Initiated the construction of a brand new 2000-sqm pilot production center.